Pain is one of the most common symptoms of cancer, reported in 52.1% of all cancer patients and \>80% of terminal cancer patients in Korea ([@b1-prm-20-293]). Active treatment, which considers the patient's pain intensity, may alleviate the patient's fear of pain, and improve treatment satisfaction and quality of life. According to the literature, immediate cancer pain management improves the patient's functional abilities and quality of life, and reduces hospital visits, thereby lowering the cost of cancer pain treatment both directly and indirectly ([@b2-prm-20-293]). Therefore, early and active management of cancer pain, based on pain intensity, is important for improving patients' satisfaction with treatment, as well as quality of life.

According to the WHO pain ladder, if pain persists or increases despite administration of nonopioids (step 1) or weak opioids (step 2), the treatment is switched to a strong opioid for moderate to severe cancer pain. According to recent recommendations, however, opioid-naive patients experiencing moderate to severe pain should receive rapid titration of short-acting opioids, and patients with chronic persistent pain controlled by stable doses of short-acting opioids should be given long-acting opioids, with a rescue dose for breakthrough pain. Although the appropriate time point for starting strong opioids should be individualized, active upfront use of strong opioids is widely accepted.

Osmotic release oral system (OROS^®^; Alza Corporation, USA) hydromorphone is a long-acting opioid formulation that provides a potent analgesic effect for cancer pain ([@b3-prm-20-293],[@b4-prm-20-293]). It maintains a constant blood concentration throughout the 24 h dosing interval, providing long-lasting analgesia ([@b5-prm-20-293]). The efficacy and safety of OROS hydromorphone was proven with a starting dose of 8 mg among chronic noncancer pain patients who were naive to strong analgesics ([@b6-prm-20-293]). However, there are very limited data demonstrating the efficacy and safety of OROS hydromorphone in cancer patients without previous exposure to a strong opioid analgesic. Recently in Europe, efficacy and safety were compared between starting doses of 4 mg and 8 mg; the lower dose (4 mg) demonstrated better tolerability and a lower number of treatment terminations at a comparable level of pain control with high treatment satisfaction ([@b7-prm-20-293]). However, this study was also limited to patients with severe, chronic, noncancer pain associated with osteoarthritis and osteoporosis. Cancer patients are more vulnerable, and experience a higher incidence of adverse events compared with noncancer patients. Therefore, it is necessary to evaluate the efficacy and safety of a long-acting strong opioid as an upfront therapy for pain management in cancer patients.

The objective of the present study was to evaluate the efficacy and tolerability of OROS hydromorphone in opioid-naive cancer patients experiencing moderate to severe cancer pain. In the present study, 4 mg of OROS hydromorphone was used as a starting dose, which is the recommended amount for noncancer patients in the literature ([@b7-prm-20-293]). The outcome of the present study will provide meaningful information on the clinical benefit of OROS hydromorphone as an upfront therapy in opioid-naive cancer patients.

METHODS
=======

Study design
------------

The present study was a prospective, open-label, multicentre, single-arm trial, conducted at 11 tertiary hospitals in South Korea from December 2011 to September 2012. It consisted of a two-week efficacy evaluation phase and a 12-week extension phase. During the efficacy evaluation, cancer pain was controlled using hydromorphone as a single strong opioid analgesic. After the efficacy evaluation, patients were given the choice to participate in the extension phase. During the extension phase, other strong opioids were permitted, if necessary, as long as OROS hydromorphone was continued.

The present study was approved by the institutional review boards of each centre, and was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines.

Study participants
------------------

Patients ≥20 years of age with an average pain intensity of ≥4 on a numerical rating scale (NRS) during the past 24 h and requiring analgesics regularly were eligible to participate. Eligible patients had not taken a long-acting strong opioid analgesic within 60 days before enrollment. Patients were excluded if they: had a history of drug or alcohol abuse within the past six months; had a history of hypersensitivity to hydromorphone; were unable to swallow solid oral formulations (eg, due to dysphagia, vomiting, paralytic ileus or intestinal obstruction); had taken monoamine oxidase inhibitors (such as moclobemide, selegiline or toloxatone) within the two-week period before study entry; were scheduled to receive radiotherapy between the first (visit 1, day 1) and second evaluation (visit 2, day 14); and had a history of radiotherapy performed on the site of current pain. All patients provided written informed consent before participation.

Drug administration and monitoring
----------------------------------

From the baseline (visit 1) to the second evaluation (visit 2), OROS hydromorphone was administered as a single, strong, long-acting opioid analgesic, to determine its clinical efficacy. Immediate-release hydromorphone was used as rescue medication; other strong opioids were not permitted during the first two weeks of the efficacy evaluation phase.

OROS hydromorphone was administered once daily with a starting dose of 4 mg and was recommended to be administered at 08:00 (±1 h). The average pain intensity over the past 24 h was evaluated by telephone inquiries every other day during the evaluation phase. If the average pain intensity was ≥4 on the NRS, or if the number of rescue analgesic administrations was ≥4 times over the past 24 h, the dose of OROS hydromorphone was elevated by 4 mg until an average pain intensity of ≤3 was achieved.

Compliance was evaluated based on the amount of leftover study drug. Patients were withdrawn from the study if they did not take the study drug for \>3 days or for \>2 consecutive days during the efficacy evaluation phase.

Opioid analgesics other than OROS hydromorphone, monoamine oxidase inhibitors, morphine agonist-antagonists, hypnotics and radiotherapies were not permitted during the two-week efficacy evaluation phase. Adjuvant drugs including acetaminophen, nonsteroidal anti-inflammatory drugs, antianxiety drugs, antidepressants, hormone therapy, corticosteroids, anticonvulsants and neuroleptics were permitted if they were administered before enrollment. However, addition or increase of the adjuvant drugs were prohibited during the efficacy evaluation phase.

Assessment
----------

The NRS and the percentage of pain relief were used to evaluate the pain intensity and efficacy of the OROS hydromorphone. The primary end point was pain intensity difference (PID) at the second evaluation (visit 2, day 14) relative to the first evaluation (visit 1, day 1), calculated as follows: $$\%\text{PID} = \lbrack\text{NRS}\,(\text{visit}\, 1) - \text{NRS}\,(\text{visit}\, 2)\rbrack/\text{NRS}\,(\text{visit}\, 1) \times 100.$$

The average pain intensity experienced by the patient over the past 24 h was evaluated using an NRS at each visit.

The secondary end points included the change in Korean Brief Pain Inventory (K-BPI) and the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) between the first evaluation and the second evaluation (Supplements 1 and 2 available at [www.pulsus.com](www.pulsus.com)). The K-BPI measured the severity of pain in the past 24 h (including 'worst', 'usual', 'least' and 'current pain'), the effect of pain on daily life performance, the location of pain, the medication used for pain management, and the extent of pain reduction over the past 24 h or the previous week, with nine questions for each evaluation area. The EORTC QLQ-C30, comprised of 30 questions, measured health status. Other secondary endpoints included the patients' and investigators' global impression on pain relief at the second evaluation. At day 14, patients and investigators were surveyed on how effective the study drug was for pain relief. The global assessment was measured on a 5-point scale: 1 -- not effective, 2 -- somewhat effective, 3 -- effective, 4 -- very effective and 5 -- extremely effective.

For the safety evaluation, adverse events were monitored throughout the study and were collected through subjects' self-reporting or indirectly by interviewers at every visit, including telephone inquiries. All adverse events were documented, and reports included the onset, severity and outcome information. In addition, the proportion of patients withdrawn from the study due to adverse events was analyzed.

Statistical analysis
--------------------

The efficacy evaluation included two sets of the population; the full analysis set (FAS) and the per-protocol (PP) set. The FAS population included patients who were administered the study drug at least once, and excluded those with major violations of the inclusion/exclusion criteria or without efficacy data collected after treatment. The PP population included patients who completed the study according to the protocol. Safety and demographic characteristics were evaluated for all patients who received the study drug at least once. Final evaluations of the primary and secondary efficacy endpoints were completed for the FAS population, and the results from the PP population were analyzed. The sample size was determined on the basis of the difference in pain intensity between before and after treatment with the study drug. For this, it was hypothesized that 60% of patients would show an improvement in pain intensity of \>50% after study drug administration. The number of patients required for 80% statistical power at a one-sided significance level of 2.5% was estimated, and the dropout rate was predicted to be 15%. The estimated number of patients required for the study was 99.

Changes in the second efficacy end points before and after drug administration were measured, and the differences were compared using a paired *t* test or Fisher's exact test for continuous variables, and a χ^2^ test or McNemar's test for categorical variables. The secondary efficacy outcomes and the safety variables were analyzed at a two-sided significance level of 5%.

RESULTS
=======

Patient disposition
-------------------

Of the 107 patients enrolled, 105 (98.1%) received the study drug at least once and were included in the safety evaluation. The FAS population included 102 patients, excluding two who did not provide efficacy data and one who violated the inclusion/exclusion criteria. The PP population included 70 (65.4%) patients, excluding 24 who were withdrawn from the study and eight who violated the protocol ([Figure 1](#f1-prm-20-293){ref-type="fig"}).

Demographics and baseline characteristics
-----------------------------------------

Demographics and baseline characteristics for 105 patients who provided safety data are presented in [Table 1](#t1-prm-20-293){ref-type="table"}. The mean (± SD) age was 63.6±11.2 years, and there was a predominance of male patients (59.1%). The most common primary site of tumour was the lung (20.0%), followed by the colorectum (17.1%) and pancreas (7.6%). Most patients had metastatic sites (78.1%) and stage IV diseases (82.9%). Seventy-four (70.5%) patients had received active anticancer treatment before enrollment ([Table 1](#t1-prm-20-293){ref-type="table"}).

Treatment compliance and extent of exposure
-------------------------------------------

Treatment compliance was evaluated at every visit. Patients were deemed to be noncompliant if they did not take the study drug for \>3 days or two consecutive days. Noncompliance was considered to be a major violation of the protocol, and four patients were noncompliant.

The mean starting dose of OROS hydromorphone was 4.1±1.2 mg/day, and the mean final dose was 7.9±6.2 mg/day. The dose of OROS hydromorphone at the end of the study was 4 mg/day in 49.5% of the patients, 8 mg/day in 31.4%, 12 mg/day in 8.6% and \>16 mg/day in 10.5%. The mean total duration of treatment was 36.6 days and mean dose was 6.3 mg/day.

Primary efficacy analysis
-------------------------

The primary efficacy end point was the difference of pain intensity measured by the proportion of patients with ≥50%PID at the second evaluation (visit 2, day 14) compared with the baseline (visit 1, day 1). Among 102 patients in the FAS population, 51.0% (n=52) achieved ≥50%PID. Among 70 patients in the PP population, 58.6% (n=41) achieved ≥50%PID ([Table 2](#t2-prm-20-293){ref-type="table"}).

The mean pain score on the NRS was 5.6±1.3 at baseline and 3.4±2.1 at the final evaluation (visit 3, week 14) in the FAS population, revealing a statistically significant difference (decrease of 2.2±2.1; P\<0.0001). The mean pain intensity decreased by 2.6±1.9 in the PP population.

For additional information, the rate of \>30% improvement in %PID (≥30%PID) at the second evaluation was analyzed. A ≥30%PID was observed in 68.6% (n=70) of the FAS population and 81.43% (n=57) of the PP population.

Secondary efficacy analysis
---------------------------

Major secondary efficacy end points included changes in the K-BPI score and EORTC QLQ-C30, as well as patients' and investigators' global assessment of pain control.

From the K-BPI score, the pain severity score (calculated by adding the scores for questions 2, 3, 4 and 5, and dividing the sum by 4) decreased from 4.8±1.2 to 3.3±1.7 with a statistically significant difference (P\<0.0001), and pain interference score (calculated by adding the scores for questions 8a, b, c, d, e, f and g, and dividing the sum by 7) also significantly decreased from 3.7±1.6 to 2.8±1.8 (P\<0.0001) in the FAS population ([Table 3](#t3-prm-20-293){ref-type="table"}).

Among 14 subscales of the EORTC QLQ-C30, statistically significant changes were observed for 10 subscales (global health status/quality of life (QoL), physical functioning, role functioning, emotional functioning, cognitive functioning, fatigue, pain, dyspnea, insomnia and diarrhea), but not for the remaining four subscales (nausea and vomiting, appetite loss, constipation and financial difficulties) in the FAS population. In the PP population, statistically significant changes were observed in 11 subscales, excluding cognitive functioning, nausea and vomiting, and constipation. The number of subscales revealing a mean change in score by \>10 points was three (global health status/QoL, pain and insomnia) in the FAS population and five (global health status/QoL, role functioning, emotional functioning, pain and insomnia) in the PP population. Pain was the subscale revealing the most significant changes (−19.8±30.4 in the FAS population and −24.3±30.1 in the PP population) ([Table 3](#t3-prm-20-293){ref-type="table"}).

Seventy-seven patients of 102 in the FAS population were evaluated for the patients' and investigators' global assessment of pain control. For the patients' global assessment, more investigators responded that the treatment was 'effective' (72.7%) than 'not effective' (27.3%). Investigators' global assessment also favoured 'effective' (74.0%) to 'not effective' (26.0%). Global assessments by the investigators and patients revealed similar results (P=0.9636) ([Table 4](#t4-prm-20-293){ref-type="table"}).

Safety and tolerability
-----------------------

Adverse events and other safety data were analyzed for 105 patients who received the study drug. Among these, 191 cases of adverse events were reported for 76 patients (72.4%), while 53 cases of adverse drug reactions were reported for 36 (34.3%) patients.

Adverse events and adverse drug reactions occurring in \>2% of patients are presented in [Table 5](#t5-prm-20-293){ref-type="table"}. The most common adverse events were nausea (15.2%), vomiting (12.4%), constipation (11.4%) and abdominal pain (5.7%), while the most common adverse drug reactions were constipation (11.4%), nausea (8.6%) and vomiting (7.6%). Thirty-seven cases of serious adverse events occurred in 28 (26.7%) patients, and most of them were related to cancer.

Of the 191 adverse events, the causal relationship with the study drug was found to be 'possible' in 43 cases (22.5%) and 'probable' in 10 cases (5.2%). The severity of adverse events were 'mild' in 113 (59.2%) cases, 'moderate' in 47 (24.6%) cases, and 'severe' in 31 (16.2%) cases. In regard to the actions taken, the study drug was discontinued in 31 (16.2%), interrupted in six (3.1%), and the dose was reduced in four (2.1%) cases and increased in three (1.6%) cases. After treatment modification, most cases (69.1%) were resolved without sequelae.

DISCUSSION
==========

The present study was a prospective, open-label, multicentre, single-arm trial to determine the efficacy and tolerability of OROS hydromorphone by measuring the PID after two weeks of hydromorphone single therapy in opioid-naive patients experiencing moderate to severe cancer pain.

Several studies have investigated the efficacy and tolerability of OROS hydromorphone in different patient groups, pain classifications and settings. Most of these studies investigated patients experiencing chronic pain who had received long-acting opioids ([@b4-prm-20-293],[@b8-prm-20-293]--[@b14-prm-20-293]). Some evaluated the efficacy and safety of OROS hydromorphone as a second-line treatment after previous long-acting opioids, such as morphine or oxycodone. However, very limited data exist on the efficacy and safety of OROS hydromorphone as front-line therapy in cancer patients. The present study involved patients who were naive to long-acting opioids, and OROS hydromorphone was used as a first-line strong opioid compound for dosing and titration.

The primary end point of the present study was %PID, and we assumed a cut-off of 50% to be a clinically meaningful decline in pain intensity. Determining the proportion of patients with a specific percentage reduction in pain intensity is widely used in the literature to evaluate treatment efficacy. A cut-off of 50% for dichotomizing pain intensity outcomes is commonly used to calculate the number needed to treat, and a 50% decline in pain intensity correlates well with other measures of pain intensity and pain relief ([@b15-prm-20-293]--[@b17-prm-20-293]). The proportion of patients with ≥50%PID after two weeks of treatment was 51.0% in the FAS population and 58.6% in the PP population; ≥30%PID was reported for 68.6% of the FAS population and 81.43% of the PP population in the additional analysis. Recently, Han et al ([@b18-prm-20-293]) reported the clinical benefit of OROS hydromorphone in patients with cancer pain inadequately controlled by other analgesics. The primary end point of their study was the PID at eight weeks later, and \>30% improvement of PID (≥30%PID) was observed in 39.2% of the FAS population and 65.2% of the PP population. They reported ≥30%PID at four weeks was obtained in 34.6% of the FAS population and 54.9% of the PP population. Compared with their study, our study demonstrated superior results within a relatively short period of time. Cepeda et al ([@b19-prm-20-293]) described the meaningful pain reduction according to pain intensity and found that a 2.4 (35%) point reduction in NRS corresponded to 'much' improvement, and 3.5 point reduction corresponded to 'very much' improvement in patients experiencing moderate pain. In our study, the average pain intensity on the NRS was reduced by 2.6 points, which is comparable for meaningful pain improvement according to Cepeda et al ([@b19-prm-20-293]).

Several extended-release oral morphine formulations are now commercially available. Avinza (Pfizer Inc, USA) was developed for once-daily dosing, similar to OROS hydromorphone. Kadian (Actavis Pharma Inc, USA) can be used once or twice per day. Studies comparing once-daily and twice-daily administrations of extended-release morphine sulfate found that there was a statistically significant preference for once-daily dosing with significantly better and earlier improvement of physical function, and without differences in pain control or tolerability ([@b20-prm-20-293],[@b21-prm-20-293]). To our knowledge, there is no direct comparative study between Avinza or Kadian and OROS hydromorphone. Avinza and OROS hydromorphone were each compared with twice-a-day oxycodone in different randomized studies ([@b6-prm-20-293],[@b21-prm-20-293]). In these studies, both Avinza and OROS hydromorphone demonstrated similar pain relief and a significantly greater improvement of sleep disturbance compared with oxycodone.

Long-acting opioids are usually indicated in opioid-tolerant patients taking at least 60 mg oral morphine per day, 25 μg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day or an equianalgesic dose of another opioid for ≥1 week(s). To follow this general guideline, it takes \>1 week to achieve proper pain control when converting to long-acting opioids from short-acting or immediate-releasing opioids. Ringe et al ([@b7-prm-20-293]) compared a lower starting dose (4 mg/day) of OROS hydromorphone to a higher starting dose (8 mg/day) in terms of tolerability, pain control and treatment satisfaction overall for subgroups of opioid-naive patients versus patients previously treated with opioids. This study was a post hoc analysis that included three different studies that used two different starting doses. Treatment satisfaction improved in a higher percentage of patients in the lower starting dose, and a lower starting dose was associated with lower overall incidence of adverse events and treatment-related events in the elderly and opioid-naive patients.

A recent study ([@b22-prm-20-293]) evaluated the effect of OROS hydromorphone on reducing the frequency of breakthrough pain medication in patients with chronic cancer pain. In that study, OROS hydromorphone was efficient in reducing the number of cancer pain-related breakthrough pain episodes, including end-of-dose pain ([@b22-prm-20-293]). However, only 15.3% (15 of 98) of patients showed a ≥50%PID, which is lower than the outcome achieved in the present study. The differences between the two studies were the frequency of pain monitoring and the use of analgesic dose elevation. We evaluated the pain intensity every other day by telephone inquiries, and the dose could be increased if the pain intensity was more than the optimal range. This monitoring technique may have facilitated more rapid and effective pain control compared with other studies.

Determining clinically important differences of the EORTC QLQ-C30 is difficult, and investigators suggested different values for each subscale. Maringwa et al ([@b22-prm-20-293]) examined a meaningful change in the EORTC QLQ-C30 in a group of lung cancer patients, and concluded that the minimal, clinically meaningful score to be 9 for physical functioning, 14 for role functioning, 5 for social functioning, 14 for fatigue and 16 for pain. Based on these criteria, physical functioning and pain revealed clinically meaningful differences in our study. Considering the evaluation was only after two weeks, other subscales should be assessed after prolonged treatment.

There were several limitations to the present study. First, the primary end point was not met because the proportion of patients with ≥50%PID was short of the level expected in sample size determination. Second, the outcome of the present study should be interpreted with caution because it was a single-arm, open-label study and a bias caused by frequent telephone inquiries cannot be ruled out. However, the present study demonstrated that initial treatment with OROS hydromorphone was safe, satisfactory and somewhat effective in opioid-naive cancer patients. It may be more beneficial and faster to achieve consistent pain control by using OROS hydromorphone from the start, rather than switching to it from other immediate-releasing opioids. Furthermore, because OROS hydromorphone is administered once daily, it offers benefits of higher treatment compliance and easy titration. Although further research in the form of randomized controlled studies will be necessary, initiating pain management with a long-acting opioid, such as OROS hydromorphone, can help opioid-naive patients to reach pain relief and improve functional performance and QoL in a short period of time.

CONCLUSION
==========

OROS hydromorphone provided effective pain relief in cancer patients, and improved activities of daily life and QoL. As a single, front-line treatment, OROS hydromorphone delivered rapid pain control, and both patients and physicians were satisfied with the level of pain management.
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###### 

Demographics and baseline characteristics (n=105)

  **Demographic**                
  ------------------------------ -----------
  **Age, years**                 
  Mean ± SD                      63.6±11.2
  Median                         65
  Minimum -- maximum             37--85
  **Male sex**                   62 (59.1)
  **Diagnosis (primary site)**   
  Lung cancer                    21 (20.0)
  Colorectal cancer              18 (17.1)
  Pancreatic cancer              8 (7.6)
  Head and neck cancer           6 (5.7)
  Cervical cancer                4 (3.8)
  Breast cancer                  4 (3.8)
  Esophageal cancer              4 (3.8)
  Endometrial cancer             2 (1.9)
  Lymphoma                       1 (1)
  Other                          37 (35.2)
  **Metastasis**                 
  No                             23 (21.9)
  Yes                            82 (78.1)
  **Stage**                      
  I                              2 (1.9)
  II                             4 (3.8)
  III                            12 (11.4)
  IV                             87 (82.9)
  **Previous therapy**           
  No                             31 (29.5)
  Yes                            74 (70.5)
    Chemotherapy                 63 (85.1)
    Radiotherapy                 16 (21.6)
    Surgery                      25 (33.8)
    Other                        4 (5.4)

Data presented as n (%) unless otherwise indicated

###### 

\% Pain intensity difference (PID) and change in average pain intensity

  **Population**      **n**   **≥50% PID**   **Change in average pain intensity**                                  
  ------------------- ------- -------------- -------------------------------------- --------- --------- ---------- ----------
  Full analysis set   102     52             51.0 (41.3--60.7)                      5.6±1.3   3.4±2.1   −2.2±2.1   \<0.0001
  Per-protocol        70      41             58.6 (47.0--70.1)                      5.6±1.3   3.0±1.3   −2.6±1.9   \<0.0001

Data presented as mean ± SD unless otherwise indicated.

P value calculated using Wilcoxon signed rank test

###### 

Korean Base Pain Inventory (K-BPI) and European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) scores

                                                                          **n**   **Baseline**   **End point**   **Mean difference**   **P[\*](#tfn4-prm-20-293){ref-type="table-fn"}**   
  ----------------------------------------------------------------------- ------- -------------- --------------- --------------------- -------------------------------------------------- -----------
  **K-BPI score**                                                                                                                                                                         
  Full analysis set                                                                                                                                                                       
    Pain severity score[^†^](#tfn5-prm-20-293){ref-type="table-fn"}       102     4.8±1.2        3.3±1.7         −1.5±1.7              −1.9 to −1.2                                       \<0.0001
    Pain interference score[^‡^](#tfn6-prm-20-293){ref-type="table-fn"}   102     3.7±1.6        2.8±1.8         −1.0±1.7              −1.3 to −0.6                                       \<0.0001
  Per-protocol                                                                                                                                                                            
    Pain severity score                                                   70      4.8±1.3        3.2±1.6         −1.6±1.6              −2.0 to −1.3                                       \<0.0001
    Pain interference score                                               70      3.8±1.6        2.7±1.7         −1.1±1.5              −1.5 to −0.8                                       \<0.0001
  **EORTC QLQ-C30**                                                                                                                                                                       
  Full analysis set                                                                                                                                                                       
    Global health status/quality of life                                  102     37.2±18.3      47.4±19.8       10.2±19.0             6.5 to 13.9                                        \<0.0001
    Physical functioning                                                  102     54.3±23.9      61.6±23.8       7.3±18.7              3.6 to 10.9                                        0.0002
    Role functioning                                                      102     45.9±31.9      38.9±29.2       −7.0±28.8             −12.7 to −1.4                                      0.0153
    Emotional functioning                                                 102     35.8±26.3      28.6±26.0       −7.2±25.0             −12.1 to −2.3                                      0.0045
    Cognitive functioning                                                 102     44.4±24.3      40.2±22.5       −4.2±18.4             −7.9 to −0.6                                       0.0218
    Fatigue                                                               102     50.4±25.5      43.1±23.2       −7.3±21.9             −11.6 to −3.0                                      0.0011
    Nausea and vomiting                                                   102     9.5±18.1       9.8±18.2        0.3±20.3              −3.7 to 4.3                                        0.8712
    Pain                                                                  102     70.4±21.1      50.7±26.9       −19.8±30.4            −25.7 to −13.8                                     \< 0.0001
    Dyspnea                                                               102     31.7±31.9      24.8±29.9       −6.9±24.5             −11.7 to −2.1                                      0.0057
    Insomnia                                                              102     51.6±34.3      38.6±33.7       −13.1±31.9            −19.3 to −6.8                                      \< 0.0001
    Appetite loss                                                         102     43.5±36.3      36.9±33.1       −6.5±34.5             −13.3 to 0.2                                       0.0584
    Constipation                                                          102     26.5±31.9      27.8±30.8       1.3±33.1              −5.2 to 7.8                                        0.6912
    Diarrhea                                                              102     8.2±20.7       3.9±12.7        −4.2±18.0             −7.8 to −0.7                                       0.0188
    Financial difficulties                                                102     44.1±34.5      39.5±33.7       −4.6±25.7             −9.6 to 0.5                                        0.0753
  Per-protocol                                                                                                                                                                            
    Global health status/quality of life                                  70      36.7±16.6      48.9±19.1       12.3±20.9             7.3 to 17.3                                        \<0.0001
    Physical functioning                                                  70      52.6±23.1      62.4±21.8       9.8±19.0              5.3 to 14.3                                        \<0.0001
    Role functioning                                                      70      45.7±31.2      35.2±25.8       −10.5±32.4            −18.2 to −2.7                                      0.0088
    Emotional functioning                                                 70      35.1±26.0      24.6±22.5       −10.5±27.0            −16.9 to −4.0                                      0.0018
    Cognitive functioning                                                 70      41.4±23.5      37.1±20.7       −4.3±19.4             −8.9 to 0.3                                        0.0687
    Fatigue                                                               70      49.0±24.3      39.4±20.0       −9.7±21.5             −14.8 to −4.6                                      0.0003
    Nausea and vomiting                                                   70      9.3±17.4       8.3±15.1        −1.0±19.0             −5.5 to 3.6                                        0.6764
    Pain                                                                  70      67.9±20.3      43.6±24.0       −24.3±30.1            −31.5 to −17.1                                     \<0.0001
    Dyspnea                                                               70      34.8±31.8      25.7±30.1       −9.0±27.2             −15.5 to −2.6                                      0.0069
    Insomnia                                                              70      45.2±32.1      28.6±27.4       −16.7±32.5            −24.4 to −8.9                                      \<0.0001
    Appetite loss                                                         70      41.9±34.4      32.9±31.3       −9.0±36.3             −17.7 to −0.4                                      0.0408
    Constipation                                                          70      26.2±31.0      27.6±30.0       1.4±38.3              −7.7 to 10.6                                       0.7556
    Diarrhea                                                              70      9.0±22.6       3.3±11.6        −5.7±21.2             −10.8 to −0.7                                      0.0274
    Financial difficulties                                                70      45.2±33.6      38.1±30.7       −7.1±24.7             −13.0 to −1.3                                      0.018

*P value calculated using a paired* t *test.*

Pain Severity Score was calculated by adding the scores for questions 2, 3, 4 and 5, and dividing the sum by 4.

Pain Interference Score was calculated by adding the scores for questions 8 a, b, c, d, e, f and g, and dividing the sum by 7

###### 

Global assessment

                             **Investigator**   **Patient**   **P[^\*^](#tfn8-prm-20-293){ref-type="table-fn"}**
  -------------------------- ------------------ ------------- ----------------------------------------------------
  **Full analysis set, n**   77                 77            0.9636
  Not effective              20 (26.0)          21 (27.3)     
    Not effective            3 (3.9)            5 (6.5)       
    Moderate                 17 (22.1)          16 (20.8)     
  Effective                  57 (74.0)          56 (72.7)     
    Effective                41 (53.3)          36 (46.8)     
    Highly effective         14 (18.2)          18 (23.4)     
    Extremely effective      2 (2.6)            2 (2.6)       
  **Per-protocol, n**        65                 65            0.9739
  Not effective              16 (24.6)          17 (26.2)     
    Not effective            3 (4.6)            5 (7.7)       
    Moderate                 13 (20.0)          12 (18.5)     
  Effective                  49 (75.4)          48 (73.9)     
    Effective                35 (53.9)          31 (47.7)     
    Highly effective         13 (20.0)          16 (24.6)     
    Extremely effective      1 (1.5)            1 (1.5)       

Data presented as n (%) unless otherwise indicated.

P values calculated using Bowker's test for symmetry

###### 

Adverse events and adverse drug reactions showing at least 2% of incidence rate

                       **Adverse event**   **Adverse drug reaction**               
  -------------------- ------------------- --------------------------- ----------- ----
  Nausea               16 (15.2)           18                          9 (8.6)     9
  Vomiting             13 (12.4)           15                          8 (7.6)     8
  Constipation         12 (11.4)           12                          12 (11.4)   12
  Abdominal pain       6 (5.7)             6                           0 (0.0)     0
  Dyspepsia            4 (3.8)             4                           2 (1.9)     2
  Cough                5 (4.8)             5                           0 (0.0)     0
  Hiccups              4 (3.8)             5                           2 (1.9)     2
  Dyspnoea             4 (3.8)             4                           0 (0.0)     0
  Asthenia             7 (6.7)             7                           0 (0.0)     0
  Decreased appetite   8 (7.6)             8                           2 (1.9)     2
  Hypophagia           6 (5.7)             6                           1 (1.0)     1
  Dizziness            6 (5.7)             6                           5 (4.8)     5
  Headache             3 (2.9)             4                           1 (1.0)     1
  Insomnia             5 (4.8)             5                           2 (1.9)     2
  Pruritus             5 (4.8)             5                           1 (1.0)     1
  Neutropenia          3 (2.9)             4                           0 (0.0)     0
  Pneumonia            3 (2.9)             3                           0 (0.0)     0
